



PRESS RELEASE

Stockholm, January 13, 2024

CombiGene has regained the global rights to the epilepsy project CG01

CombiGene AB (publ) ("CombiGene", "the Company") today announces that the Company has regained the global rights to the epilepsy project CG01 from Spark Therapeutics ("Spark") as the termination period of the collaboration and license agreement between the two companies has expired, see press release dated October 14, 2023.

"Going forward, it is CombiGene's ambition to find a new partner for the CG01 project," says Peter Ekolind, CombiGene's CEO. "Finding a new partner for the epilepsy project is of course a top priority for CombiGene, and we will take the time and efforts necessary to put together an attractive proposition for potential partners," Peter concludes.

About the epilepsy project CG01

CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.

About CombiGene AB

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company's Certified Advisor is FNCA Sweden AB.

For more information:

CombiGene AB (publ)

Peter Ekolind, CEO

Tel: +46 (0)70-341 55 60

peter.ekolind@combigene.com

Please read "Ingeneious", a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com